Loading clinical trials...
Loading clinical trials...
Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
Conditions
Interventions
Cabozantinib monotherapy
All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
Locations
1
United States
McKesson Life Sciences
The Woodlands, Texas, United States
Start Date
January 30, 2020
Primary Completion Date
June 5, 2020
Completion Date
June 5, 2020
Last Updated
November 17, 2021
Lead Sponsor
Ipsen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions